Anti-Corruption and Anti-Bribery

Teva Baltics / Sicor Biotech UAB, as part of the Teva group, is subject to various anti-corruption and anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act.

As such, we comply with Teva's Anti-Corruption Policy and we expect everyone who does business with Teva to also comply with our Anti-Corruption Policy. The purpose of this policy is to provide detailed guidance for complying with anti-corruption and anti-bribery laws that are applicable to all Teva entities and activities worldwide.
 
The scope of this policy is the relationship between Teva, any government officials and any other 3rd parties acting on behalf of Teva (as defined within the policy). For more information, download the full Policy.
 
 
The Compliance Officer Nordics and Baltics is Helle Grinderslev Kramp – in any case of doubt please call +45 44 98 55 11 or write an e-mail Helle.Kramp@tevapharm.dk
 

Teva Baltics / Sicor Biotech UAB are highly responsible to comply with local regulations of the countries we operate in.

 

Estonian Disclosure of Values

According to APME ( Association of Estonian Pharmaceutical Companies ) Ethical code supplement effective from January 1, 2016 APME member companies should disclose donations and grants, contribution to event related costs such as registration fees, travel and accommodation costs, fees for service and consultancy paid either directly or indirectly to health care professionals and pharmacists or health care providers by June 1st .

Disclosure of values - Report 2016

Disclosure of values - Report 2015

 
 
Lithuanian Disclosure of Values
The Disclosure Code which is  part of the Code of Ethics for Pharmaceutical Marketing imposes obligations to disclose transfers of value to healthcare professionals and healthcare organisations in Lithuania.
 
 
 
Latvian Disclosure of Values

About the EFPIA Disclosure Code

To ensure full transparancy of collaboration between the company and HCP/HCO (healthcare professionals/organisations), Teva as a member of Latvian Generic Medicines Association discloses transfers of value to healthcare professionals and healthcare organisations. This information is published in accordance with EFPIA (European Federation of Pharmaceutical Industries and Associations) Disclosure Code.

The first disclosure will be made by 30 June 2016, for transfers of value made in 2015.

Disclosure of values